Anti-CD16-anti-CD30 monoclonal antibody

N/A

Report date: 2022/03/30 14:39:22

Base Information

Drug NameAnti-CD16-anti-CD30 monoclonal antibody

Drug Alias NameAnti-CD30-anti-CD16 monoclonal antibodyAnti-CD16-anti-CD30 bispecific monoclonal antibodyAnti-CD30-anti-CD16 bispecific monoclonal antibody

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionAnti-Low affinity immunoglobulin gamma Fc region receptor III-AAnti-Tumor necrosis factor receptor superfamily member 8

TargetsLow affinity immunoglobulin gamma Fc region receptor III-ATumor necrosis factor receptor superfamily member 8

Therapy Area/IndicationsHodgkin Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiotest Pharma Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBiotest Ag

Active IndicationsN/A

Inactive IndicationsHodgkin Disease

Other Information

ATC CodeN/A